JP

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Hong Kong (China) *

Republic of Korea *

img-impact-of-pan-kras-inhibitors-on-cancer-drug-discovery1920x640

Literature - Publication Review

The impact of pan-KRAS inhibitors on cancer drug discovery

The KRAS pathway was considered "undruggable". Read how Revvity's preclinical services helped Boehringer Ingelheim generate compounds to target this pathway.

In this literature review you will learn:

An overview of the challenges around KRAS inhibition
The approach the researchers took to develop and evaluate pan-KRAS inhibitors for their ability to combat carcinogenesis
Key findings from the study and the role that Revvity's cell panel screening services played

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

営業担当者から連絡を受けることに同意します。

お名前（名）

お名前（姓）

国

メールアドレス

会社名

郵便番号

勤務先電話番号

職種

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

The impact of pan-KRAS inhibitors on cancer drug discovery

Download Literature - Publication Review